16:04:35 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-03-21 X-dag ordinarie utdelning FLUO 0.00 DKK
2024-03-20 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-29 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-03-22 X-dag ordinarie utdelning FLUO 0.00 DKK
2023-03-21 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-19 X-dag ordinarie utdelning FLUO 0.00 DKK
2022-05-18 Årsstämma 2022
2022-03-30 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-03 X-dag ordinarie utdelning FLUO 0.00 DKK
2021-02-26 Bokslutskommuniké 2020
2021-02-09 Årsstämma 2021
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-14 Kvartalsrapport 2020-Q2
2020-05-27 Kvartalsrapport 2020-Q1
2020-04-09 X-dag ordinarie utdelning FLUO 0.00 DKK
2020-04-08 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-05-31 Kvartalsrapport 2019-Q1

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
FluoGuide är ett danskt bolag verksamma inom medicinteknik. Bolaget affärsfokus återfinns inom forskning och utveckling av behandlingar mot olika cancerformer, med störst fokus på utveckling av produkter som vägleder vid kirurgiska ingrepp. Produkterna binder till sig cancercellerna som då lyser upp och är avsedda att användas för att med precision kunna ta bort skadliga tumörer i patientens vävnad.
2023-11-29 08:00:00

Copenhagen, Denmark, 29 November 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January – 30 September 2023. The Q3 report is available as an attached document to this press release and on FluoGuide’s website.

In Q3 2023, FluoGuide completed patient recruitment for two clinical phase II trials of FG001, in aggressive brain cancer and head and neck cancers. The positive results in these indications, some of which were published after the end of Q3, as well as positive phase II data in lung cancer reported earlier in 2023, put FluoGuide in a uniquely promising position. Financial flexibility enables the Company to fully capitalize on the good clinical results.
 
FluoGuide had no revenue for the period and posted a net result of TDKK -9,314 (TDKK -7,041) for the period 1 January to 30 September 2023. The financial result for the period is in line with the Company's development plans.
 

SummaryQ3 23Q3 22YTD 2023YTD 20222022
DKK thousands1-Jul-231-Jul-221-Jan-231-Jan-221-Jan-22
 30-Sep-2330-Sep-2230-Sep-2330-Sep-2231-Dec-22
Net Revenue-----
Operating result-10,862-8,416-31,164-21,358-32,461
Net result-9,314-7,041-25,990-16,743-27,340
Cash and bank8,94531,7008,94531,70026,013
      
Result per share (DKK) *)-0.78-0.60-2.19-1.43-2.33
Solidity (%) **)73%91%73%91%90%

 *) Result per share (DKK per share): Operating result divided by the average number of shares during the period.
**) Solidity: Total equity divided by total capital and liability.

HIGHLIGHTS DURING Q2:

  • Positive interim data from phase lla trial of FG001 in head & neck cancer presented as a case report at the World Molecular Imaging Congress in Prague
  • Further positive interim data from phase lla trial of FG001 in head & neck cancer
  • Completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer
  • Completes a Directed Share Issue raising SEK 15 million
  • Issues warrants to Board members, management, and employees, as well as the investors participating in the Directed Share Issue

HIGHLIGHTS AFTER Q2

  • Receives FDA Orphan Drug Designation for FG001 in high-grade glioma
  • Confirms positive topline results from phase lla trial of FG001 in head & neck cancer at IAOO
  • Announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer

For further information, please contact:
Morten Albrechtsen, CEO,
FluoGuide A/S
+45 24 25 62 66,
ma@fluoguide.com

About FluoGuide
FluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer intraoperatively. This improved precision enabled by FluoGuide’s products is expected to have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs.

The Company has published key results on the efficacy of FG001 as well as showing it was well tolerated and safe from clinical trials in patients with aggressive brain cancer (high-grade glioma) that undergo surgery. In addition, FluoGuide has demonstrated the effect of FG001 in lung and head & neck cancers.

For more information on the Company, please visit www.fluoguide.com